Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid.
Sophia KrasnyCynthia YanSigan L HartleyBen L HandenJulie K WischAnna H BoehrwinkleBeau M AncesMichael S Rafiinull nullPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
There is rapid increase in prevalence of amyloid beta (Aβ) positron emission tomography (PET) positivity in Down syndrome (DS) after the age of 40 years. Aβ PET positivity thresholds have significant impact on prevalence rates in DS. There is a significant lag between Aβ PET positivity and clinical symptom onset in DS.